Xcout Intel
iOmx Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to iOmx Therapeutics among biotechnology companies — ranked by similarity to what iOmx Therapeutics actually does, not by market-cap band.
Subscribe to see iOmx Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About iOmx Therapeutics
iOmx Therapeutics AG is a biopharmaceutical company located in Martinsried near Munich, Germany, dedicated to discovering and developing next-generation targeted cancer immunotherapies.
iOmx Therapeutics at a glance
iOmx Therapeutics is a biotechnology company headquartered in Germany. It has raised at least $122.5M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $75.4M in October 2021. Xcout tracks 11 named people at iOmx Therapeutics, including Apollon Papadimitriou (Chief Executive Officer).
iOmx Therapeutics leadership
- Apollon PapadimitriouChief Executive Officer
- Rüdiger WolffChief Financial Officer
- Christine RotheChief Development Officer
- Hannes LofererChief Operations Officer
- Tiantom JarutatChief Medical Officer
- Gerald H. MoellerChairman of the Supervisory Board
5 more named people on record for iOmx Therapeutics, with roles, board committees and tenure — see the full roster →
iOmx Therapeutics funding rounds
At least $122.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $75.4M | 7 named | |
| Series A | $47.1M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 iOmx Therapeutics competitors
Ranked by semantic similarity — how close each company is to iOmx Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Immatics is a biopharmaceutical company that develops T cell-based immunotherapies and bispecific product candidates to treat various types of cancer. The company focuses on precision targeting of the PRAME protein expressed in multiple solid tumors, serving cancer patients with high unmet medical needs.
Similar biotechnology company
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
Similar biotechnology company
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Similar biotechnology company
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
Similar biotechnology company
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
Similar biotechnology company
Immunomic Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, that develops innovative immune therapies.
Similar biotechnology company
Umoja Biopharma is a biotechnology research company headquartered in Seattle, Washington, focused on developing next-generation immunotherapies.
Similar biotechnology company
IO Biotech, Inc. is a clinical-stage biopharmaceutical company that develops novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines. Its proprietary T-win® technology is designed to modulate the tumor microenvironment by targeting both tumor cells and immune-suppressive cells, aiming to improve treatment outcomes for patients with melanoma and other tumor types.
Similar biotechnology company
Imvax, Inc. is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing personalized, whole-cell immunotherapies for the treatment of various cancers.
Similar biotechnology company
Oncomatryx is a Spanish biopharmaceutical company headquartered in Derio, Basque Country, Spain. The firm pioneers targeted oncology therapeutics aimed at treating metastatic solid tumors and utilizes advanced computational approaches in its drug discovery pipeline.
Similar biotechnology company
Affimed Therapeutics is a biotechnology company focused on developing cancer immunotherapies that recruit and activate innate immune cells, particularly natural killer (NK) cells, to attack tumor cells. Its investigational products are intended for oncology patients and are developed for use by cancer-care providers.
Similar biotechnology company
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of iOmx Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for iOmx Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →